Evidence map›Paper›PMID 39361181›Full record

ArticleClinical and experimental nephrology2025

Outcomes of kidney transplantation in recipients with SARS-cov-2 infection: a 282-case single-center experience in Japan.

Eri Sekido, Kohei Unagami, Kazuya Omoto, Ken Arimura, Ikumi Moriyama, Taro Banno, Ayaka Saitoh, Rikako Oki, Daigo Okada, Takafumi Yagisawa and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical and experimental nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Eri SekidoDepartment of Urology, Tokyo Women's Medical University, Tokyo, Japan.
Kohei UnagamiDepartment of Nephrology, Tokyo Women's Medical University, Tokyo, Japan. unagami.kohei@twmu.ac.jp.ORCID http://orcid.org/0000-0001-7309-0658
Kazuya OmotoDepartment of Urology, Tokyo Women's Medical University, Tokyo, Japan.
Ken ArimuraDepartment of Pulmonology, Tokyo Women's Medical University, Tokyo, Japan.
Ikumi MoriyamaDepartment of Urology, Tokyo Women's Medical University, Tokyo, Japan.
Taro BannoDepartment of Urology, Tokyo Women's Medical University, Tokyo, Japan.
Ayaka SaitohDepartment of Organ Transplant Medicine, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan.
Rikako OkiDepartment of Organ Transplant Medicine, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan.
Daigo OkadaDepartment of Urology, Tokyo Women's Medical University, Tokyo, Japan.
Takafumi YagisawaDepartment of Urology, Tokyo Women's Medical University, Tokyo, Japan.
Taichi KanzawaDepartment of Urology, Tokyo Women's Medical University, Tokyo, Japan.
Kumiko KitajimaDepartment of Organ Transplant Medicine, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan.
Toshihito HiraiDepartment of Urology, Tokyo Women's Medical University, Tokyo, Japan.
Tomokazu ShimizuDepartment of Urology, Tokyo Women's Medical University, Tokyo, Japan.
Shigeyoshi YamanagaDepartment of Surgery, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan.
Hiroto EgawaDepartment of Surgery, Tokyo Women's Medical University, Tokyo, Japan.
Masashi InuiDepartment of Urology, Tokyo Women's Medical University, Tokyo, Japan.
Junichi HoshinoDepartment of Nephrology, Tokyo Women's Medical University, Tokyo, Japan.
Hideki IshidaDepartment of Organ Transplant Medicine, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan.
Toshio TakagiDepartment of Urology, Tokyo Women's Medical University, Tokyo, Japan.

Funding

MHLW Research Program on Emerging and Reemerging Infectious Diseases (JP) JPMH21HA2011MHLW Special Research Program (JP) JPMH20CA2046
6 · The paper itself

Abstract

backgroundThe coronavirus disease 2019, caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), has become a global epidemic. There are concerns regarding the severity of SARS-CoV-2 infections in kidney transplant (KTx) recipients. However, there is limited data on how the epidemic has affected the treatment and prognosis of these patients. Therefore, we aimed to report the changes in the treatment and outcomes of KTx recipients infected with SARS-CoV-2 during each wave at our institution.

methodsA total of 282 KTx recipients who were infected with SARS-CoV-2 during the study period were followed up at Tokyo Women's Medical University between March 2020 and August 2022. We investigated the outcomes and treatments of infected KTx recipients.

resultsNineteen (6.7%) patients showed severe outcomes, including eight SARS-CoV-2 infection-related deaths. Risk factors associated with severe outcomes included underlying conditions, such as diabetes mellitus, heart disease, and liver disease (odds ratios, 2.09, 2.88, and 5.52, respectively). Treatment strategies changed throughout the epidemic in response to changes in the SARS-CoV-2 variants. Antiviral drugs were gradually administered as soon as they were approved for use.

conclusionsTreatment strategies for KTx recipients were gradually established over the course of the epidemic. Although the proportion of infected KTx recipients decreased compared to that of the general population throughout the epidemic, many patients still followed a severe course.

Indexed as

Antiviral AgentsCOVID-19Kidney TransplantationAdultAgedCOVID-19 Drug TreatmentFemaleHumansJapanMaleMiddle AgedRetrospective StudiesRisk FactorsSARS-CoV-2Treatment OutcomeAntiviral AgentsCOVID-19Immunosuppressive therapyKidney transplantationSARS-CoV-2

Identifiers

PMID39361181

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.